Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.
STUDY14725 LUNGMAP: A Master Protocol To Evaluate Biomarker Driven Therapies And Immunotherapies In Previously Treated Non Small Cell Lung Cancer (Lung Map Screening Study) This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies. Study Information
STUDY20133 Pediatric Acute Leukemia (PedAL) Screening Trial Developing New Therapies for Relapsed Leukemias To utilize clinical and biological characteristics of acute leukemias to screen for patient eligibility for available Phase I/II PedAL sub-trials. To maintain a longitudinal and comprehensive registry from relapse in children and young adults with recurrent and refractory leukemia. Study Information
STUDY21784 Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancer The primary objective of this study is to determine the proportion of patients with stage IA2-III lung cancers who possess actionable oncogenic drivers. The screening approach will be considered feasible if, utilizing tumor or plasma assays, 35% of non-squamous non-small cell lung cancers are identified as having a actionable genomic alteration including ALK rearrangements, BRAFV600E mutations, EGFR sensitizing mutations, HER2 mutation, HER2 amplification, MET amplification, MET exon 14 mutation, RET rearrangements, NTRK rearrangement, KRAS G12C, or ROS1 rearrangements Study Information
STUDY22276 Advanced Precision Observational Lung Living Outcomes: Lung Cancer Screening Study The objective of this study is to develop new and/or validate a panel of blood-based biomarkers and candidate classifiers developed by PrognomiQ for lung cancer detection in patients undergoing lung cancer screening. Study Information
STUDY23307 TEMPUS GEMINI NSCLC STUDY: A Longitudinal Multi Omic Biomarker Profiling Study of Patients with Non Small Cell Lung Cancer (NSCLC) Primary Objectives: To prospectively determine if a plasma-only ctDNA methylation based minimum residual disease (MRD) assay (i.e., xM) completed one month post-surgical resection +/- adjuvant therapy can predict recurrence in patients with Stage I-IIIa NSCLC at a minimum of two year follow up. To prospectively determine if plasma-only ctDNA methylation based MRD assay (i.e., xM) completed one month post systemic therapy can predict recurrence or progression in patients with Stage IIIb-IV NSCLC at a minimum of one year follow up. Endpoints: Recurrence-Free Survival (RFS) or Progression-Free Survival (PFS) as assessed by standard radiographic imaging. Secondary Objectives: To determine the performance of a plasma-only ctDNA methylation-based MRD assay through serial testing To assess concordance between molecular biomarkers detected in the tumor tissue and in plasma ctDNA using a broad-based tissue and liquid NGS assays (i.e., xT and xF, respectively) To characterize test performance by disease stage. Endpoints: Sensitivity and specificity; RFS or PFS Percentage of variants detected by both assays Subgroup analysis of sensitivity and specificity by stage. Exploratory Objectives: To characterize the relationship between genomic results (xT, xF, xM) and clinical outcomes based on collection of longitudinal information from medical records To determine if surgical biopsy introduces ctDNA into the bloodstream To study tumor heterogeneity by comparing molecular results from biopsy and resection for patients with early-stage and locally advanced NSCLC. Endpoints: Clinical outcomes based on xT, xF, xM assay results Compare ctDNA detected before and after biopsy Variants detected from biopsy specimen vs. surgical resection specimen from the same patient Study Information